A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

Nature Genetics

Volumn 46, Issue 10, 2014, Pages 1103-1109

  Olama, Ali Amin Al ^a   Kote Jarai, Zsofia ^b   Berndt, Sonja I ^c   Conti, David V ^d,e   Schumacher, Fredrick ^d,e   Han, Ying ^d   Benlloch, Sara ^a   Hazelett, Dennis J ^d,e   Wang, Zhaoming ^c,f   Saunders, Ed ^b   Leongamornlert, Daniel ^b   Lindstrom, Sara ^g   Jugurnauth Little, Sara ^b   Dadaev, Tokhir ^b   Tymrakiewicz, Malgorzata ^b   Stram, Daniel O ^d,e   Rand, Kristin ^d   Wan, Peggy ^d   Stram, Alex ^d   Sheng, Xin ^d   Pooler, Loreall C ^d   Park, Karen ^d   Xia, Lucy ^d   Tyrer, Jonathan ^a   Kolonel, Laurence N ^h   Marchand, Loic Le ^h   Hoover, Robert N ^c   Machiela, Mitchell J ^c   Yeager, Merideth ^c   Burdette, Laurie ^c   Chung, Charles C ^c   Hutchinson, Amy ^c   Yu, Kai ^c   Goh, Chee ^b   Ahmed, Mahbubl ^b   Govindasami, Koveela ^b   Guy, Michelle ^b   Tammela, Teuvo L J ⁱ   Auvinen, Anssi ^j   Wahlfors, Tiina ^j   Schleutker, Johanna ^j,k   Visakorpi, Tapio ^j   Leinonen, Katri A ^j   Xu, Jianfeng ^l   Aly, Markus ^m,n   Donovan, Jenny ^o   Travis, Ruth C ^p   Key, Tim J ^p   Siddiq, Afshan ^q   Canzian, Federico ^r   Khaw, Kay Tee ^a   Takahashi, Atsushi ^s   Kubo, Michiaki ^s   Pharoah, Paul ^a   Pashayan, Nora ^a   Weischer, Maren ^t   Nordestgaard, Borge G ^t,u   Nielsen, Sune F ^t,u   Klarskov, Peter ^t   Røder, Martin Andreas ^v   Iversen, Peter ^v   Thibodeau, Stephen N ^w   McDonnell, Shannon K ^w   Schaid, Daniel J ^w   Stanford, Janet L ^x,y   Kolb, Suzanne ^x   Holt, Sarah ^x   Knudsen, Beatrice ^z   Coll, Antonio Hurtado ^aa   Gapstur, Susan M ^ab   Diver, W Ryan ^ab   Stevens, Victoria L ^ab   Maier, Christiane ^ac   Luedeke, Manuel ^ac   Herkommer, Kathleen ^ad   Rinckleb, Antje E ^ac   Strom, Sara S ^ae   Pettaway, Curtis ^ae   Yeboah, Edward D ^af,ag   Tettey, Yao ^af,ag   Biritwum, Richard B ^af,ag   Adjei, Andrew A ^af,ag   Tay, Evelyn ^af,ag   Truelove, Ann ^ah   Niwa, Shelley ^ah   Chokkalingam, Anand P ^ai   Cannon Albright, Lisa ^aj,ak   Cybulski, Cezary ^al   Wokołorczyk, Dominika ^al   Kluźniak, Wojciech ^al   Park, Jong ^am   Sellers, Thomas ^am   Lin, Hui Yi ^am   Isaacs, William B ^an   Partin, Alan W ^an   Brenner, Hermann ^r   Dieffenbach, Aida Karina ^r   Stegmaier, Christa ^ao   Chen, Constance ^g   Giovannucci, Edward L ^g   Ma, Jing ^ap   Stampfer, Meir ^g   Penney, Kathryn L ^g,ap   Mucci, Lorelei ^g,ap   John, Esther M ^aq,ar   Ingles, Sue A ^d,e   Kittles, Rick A ^as   Murphy, Adam B ^at   Pandha, Hardev ^au   Michael, Agnieszka ^au   Kierzek, Andrzej M ^au   Blot, William ^av,aw   Signorello, Lisa B ^g,ap   Zheng, Wei ^aw   Albanes, Demetrius ^c   Virtamo, Jarmo ^ax   Weinstein, Stephanie ^c   Nemesure, Barbara ^ay   Carpten, John ^az   Leske, Cristina ^ay   Wu, Suh Yuh ^ay   Hennis, Anselm ^ay,ba   Kibel, Adam S ^bb   Rybicki, Benjamin A ^bc   Neslund Dudas, Christine ^bc   Hsing, Ann W ^aq,ar   Chu, Lisa ^aq,ar   Goodman, Phyllis J ^bd   Klein, Eric A ^be   Zheng, S Lilly ^l   Batra, Jyotsna ^bf   Clements, Judith ^bf   Spurdle, Amanda ^bg   Teixeira, Manuel R ^bh,bi   Paulo, Paula ^bh   Maia, Sofia ^bh   Slavov, Chavdar ^bj   Kaneva, Radka ^bj   Mitev, Vanio ^bj   Witte, John S ^bk,bl   Casey, Graham ^d,e   Gillanders, Elizabeth M ^c   Seminara, Daniella ^c   Riboli, Elio ^q   Hamdy, Freddie C ^p   Coetzee, Gerhard A ^d,e   Li, Qiyuan ^bm   Freedman, Matthew L ^bm   Hunter, David J ^g   Muir, Kenneth ^bn,bo   Gronberg, Henrik ^m   Neal, David E ^bp,bq   Southey, Melissa ^br   Giles, Graham G ^bs,bt   Severi, Gianluca ^bs,bt,bu   Cook, Michael B ^c   Nakagawa, Hidewaki ^s   Wiklund, Fredrik ^m   Kraft, Peter ^g   Chanock, Stephen J ^c   Henderson, Brian E ^d,e   Easton, Douglas F ^a   Eeles, Rosalind A ^b,bv   Haiman, Christopher A ^d,e   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF HAWAII CANCER CENTER   (United States)

ⁱ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^j TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^k UNIVERSITY OF TURKU   (Finland)

^l WAKE FOREST SCHOOL OF MEDICINE   (United States)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ DANDERYD HOSPITAL   (Sweden)

^o UNIVERSITY OF BRISTOL   (United Kingdom)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^s RIKEN Center for Integrative Medical Sciences   (Japan)

^t GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^u UNIVERSITY OF COPENHAGEN   (Denmark)

^v Rigshospitalet   (Denmark)

^w MAYO CLINIC   (United States)

^x Fred Hutchinson Cancer Research Center   (United States)

^y UNIVERSITY OF WASHINGTON   (United States)

^z CEDARS SINAI MEDICAL CENTER   (United States)

^aa Prostate Cancer Center   (Canada)

^ab AMERICAN CANCER SOCIETY   (United States)

^ac UNIVERSITY HOSPITAL ULM   (Germany)

^ad TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^ae UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^af UNIVERSITY OF GHANA   (Ghana)

^ag KORLE BU TEACHING HOSPITAL   (Ghana)

^ah WESTAT   (United States)

^ai UNIVERSITY OF CALIFORNIA   (United States)

^aj UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^ak VETERANS AFFAIRS MEDICAL CENTER   (United States)

^al POMERANIAN MEDICAL UNIVERSITY   (Poland)

^am H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^an JOHNS HOPKINS HOSPITAL   (United States)

^ao SAARLAND CANCER REGISTRY   (Germany)

^ap HARVARD MEDICAL SCHOOL   (United States)

^aq CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^ar STANFORD CANCER INSTITUTE   (United States)

^as UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^at NORTHWESTERN UNIVERSITY   (United States)

^au UNIVERSITY OF SURREY   (United Kingdom)

^av INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^aw VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ax NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^ay STONY BROOK UNIVERSITY   (United States)

^az TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^ba UNIVERSITY OF THE WEST INDIES   (Jamaica)

^bb BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bc HENRY FORD HOSPITAL   (United States)

^bd SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^be LERNER RESEARCH INSTITUTE   (United States)

^bf QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^bg QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^bh PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^bi UNIVERSITY OF PORTO   (Portugal)

^bj MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^bk UNIVERSITY OF CALIFORNIA   (United States)

^bl UNIVERSITY OF CALIFORNIA   (United States)

^bm DANA FARBER CANCER INSTITUTE   (United States)

^bn UNIVERSITY OF MANCHESTER   (United Kingdom)

^bo UNIVERSITY OF WARWICK   (United Kingdom)

^bp IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^bq UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^br UNIVERSITY OF MELBOURNE   (Australia)

^bs CANCER EPIDEMIOLOGY CENTRE   (Australia)

^bt UNIVERSITY OF MELBOURNE   (Australia)

^bu Human Genetics Foundation   (Italy)

^bv INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; LONG UNTRANSLATED RNA; PROSTATE SPECIFIC ANTIGEN; STAT1 PROTEIN; TRANSCRIPTION FACTOR ERG;

ADULT; AFRICAN; ALLELE; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CELL ADHESION; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME 6P; CHROMOSOME 9P; CHROMOSOME TRANSLOCATION; CHROMOSOME XQ; DISEASE SEVERITY; EARLY CANCER; ENHANCER REGION; EUROPEAN; GENE; GENE CLUSTER; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; GLIOMA; HISPANIC; HUMAN; HUMAN CELL; HUMAN GENOME; JAPANESE (PEOPLE); LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SINGLE NUCLEOTIDE POLYMORPHISM; TMPRSS2 GENE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR;

GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84922011640     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3094     Document Type: Article

References (48)

1. Eeles, R. et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 11, 18-31 (2014).
2. Eeles, R.A. et al. Identifcation of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45, 385-391 (2013).
3. Park, J.H. et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42, 570-575 (2010).
4. Eeles, R.A. et al. Multiple newly identifed loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316-321 (2008).
5. Gudmundsson, J. et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122-1126 (2009).
6. Schumacher, F.R. et al. Genome-wide association study identifes new prostate cancer susceptibility loci. Hum. Mol. Genet. 20, 3867-3875 (2011).
7. Thomas, G. et al. Multiple loci identifed in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008).
8. Cheng, I. et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol. Biomarkers Prev. 21, 2048-2058 (2012).
9. Haiman, C.A. et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 7, e1001387 (2011).
10. Duggan, D. et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl. Cancer Inst. 99, 1836-1844 (2007).
11. Haiman, C.A. et al. Genome-wide association study of prostate cancer in men of African ancestry identifes a susceptibility locus at 17q21. Nat. Genet. 43, 570-573 (2011).
12. Cook, M.B. et al. A genome-wide association study of prostate cancer in West African men. Hum. Genet. 133, 509-521 (2014).
13. Akamatsu, S. et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat. Genet. 44, 426-429 (2012).
14. Takata, R. et al. Genome-wide association study identifes fve new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42, 751-754 (2010).
15. Sun, J. et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 69, 10-15 (2009).
16. Hedstrom, L. Serine protease mechanism and specifcity. Chem. Rev. 102, 4501-4524 (2002).
17. Morris, D.S., Tomlins, S.A., Montie, J.E. & Chinnaiyan, A.M. The discovery and application of gene fusions in prostate cancer. BJU Int. 102, 276-282 (2008).
18. Falchi, M. et al. Genome-wide association study identifes variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915-919 (2009).
19. Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15-21 (1994).
20. Shete, S. et al. Genome-wide association study identifes fve susceptibility loci for glioma. Nat. Genet. 41, 899-904 (2009).
21. Stacey, S.N. et al. New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41, 909-914 (2009).
22. Turnbull, C. et al. Genome-wide association study identifes fve new breast cancer susceptibility loci. Nat. Genet. 42, 504-507 (2010).
23. Wrensch, M. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905-908 (2009).
24. Timofeeva, M.N. et al. Infuence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum. Mol. Genet. 21, 4980-4995 (2012).
25. Tikhmyanova, N., Little, J.L. & Golemis, E.A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 67, 1025-1048 (2010).
26. Loikkanen, I. et al. Myosin VI is a modulator of androgen-dependent gene expression. Oncol. Rep. 22, 991-995 (2009).
27. Puri, C. et al. Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 29, 188-200 (2010).
28. Wei, S., Dunn, T.A., Isaacs, W.B., De Marzo, A.M. & Luo, J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 68, 1387-1395 (2008).
29. Michailidou, K. et al. Large-scale genotyping identifes 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353-361 (2013).
30. Howie, B.N., Donnelly, P. & Marchini, J. A fexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
31. Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11, 134 (2010).
32. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and effcient meta-analysis of genomewide association scans. Bioinformatics 26, 2190-2191 (2010).
33. Hazelett, D.J. et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 10, e1004102 (2014).
34. Thurman, R.E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75-82 (2012).
35. Coetzee, S.G., Rhie, S.K., Berman, B.P., Coetzee, G.A. & Noushmehr, H. FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. Nucleic Acids Res. 40, e139 (2012).
36. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defned by eRNA. Nature 474, 390-394 (2011).
37. Tan, P.Y. et al. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol. Cell. Biol. 32, 399-414 (2012).
38. Andreu-Vieyra, C. et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol. Cell. Biol. 31, 4648-4662 (2011).
39. Sharma, N.L. et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23, 35-47 (2013).
40. Jeggari, A., Marks, D.S. & Larsson, E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 28, 2062-2063 (2012).
41. Wang, J. et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 22, 1798-1812 (2012).
42. Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633-641 (2013).
43. Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 321, 129-135 (1989).
44. Irizarry, R.A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
45. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
46. Summersgill, B., Clark, J. & Shipley, J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fxed paraffn embedded material, including tissue microarrays. Nat. Protoc. 3, 220-234 (2008).
47. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882-888 (2007).
48. Saramäki, O.R. et al. TMPRSS2:ERG fusion identifes a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 14, 3395-3400 (2008).